A Study of Vedolizumab for Treatment of Graft-Versus-Host Disease (GvHD) that has not responded to steroid treatment in patients who have had stem cell transplantation

Update Il y a 4 ans
Reference: EUCTR2016-002985-30

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective is to describe the initial activity, tolerability, and safety and to identify a recommended dose and regimen of vedolizumab IV administered for treatment of steroid-refractory acute intestinal GvHD in patients who have undergone allo-HSCT.


Inclusion criteria

  • Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD)

Links